Comparison of line probe assay (LIPA) and sequence analysis for detection of HIV-1 drug resistance

Journal of Medical Virology

Volumn 57, Issue 3, 1999, Pages 283-289

  Puchhammer Stöckl, Elisabeth ^a   Schmied, Brigitte ^b   Mandl, Christian W ^a   Vetter, Norbert ^b   Heinz, Franz X ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b Pulmologisches Zentrum   (Austria)

Author keywords

Drug resistance; HIV; LIPA; Sequence analysis

Indexed keywords

ANTIRETROVIRUS AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ADULT; ANALYTIC METHOD; ANTIBIOTIC RESISTANCE; ARTICLE; CHILD; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DNA DETERMINATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOASSAY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; NONHUMAN; SEQUENCE ANALYSIS; VIRUS GENOME; VIRUS MUTANT; VIRUS MUTATION; VIRUS STRAIN;

ADULT; ANTI-HIV AGENTS; CHILD; CODON; DRUG RESISTANCE, MICROBIAL; GENOME, VIRAL; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; IMMUNOASSAY; MUTATION; NUCLEOSIDES; SEQUENCE ANALYSIS, DNA;

EID: 0032929938     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9071(199903)57:3<283::AID-JMV12>3.0.CO;2-2     Document Type: Article

References (25)

1. Boucher CA, O'Sullivan E, Mulder JW, Ramautarsing C, Kellam P, Darby G, Lange JM, Goudsmit J, Larder BA. 1992. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J Inf Dis 165: 105-110.
2. Carpenter CJ, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schooley RT, Thompson MA. Vella S, Yeni PG, Volberding PA. 1997. Antiretroviral therapy for HIV infection in 1997. JAMA 277:1962-1969.
3. De Jong M-D, Veenstra J, Stilianakis NI, Schuurman R, Lange JM, De Boer RJ, Boucher CA. 1996. Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine. Proc Natl Acad Sci 93:5501-5506.
4. Eastman PS, Boyer E, Mole L, Kolberg J, Urdea M, Holodniy M. 1995. Nonisotopic hybridization assay for determination of relative amounts of genotypic human immunodeficiency virus type 1 zidovudine resistance. J Clin Microbiol 33:2777-2780.
5. Erice A, Douglas MD, Mayers L, Strike DG, Sannerud KJ, McCutchan FE, Henry K, Balfour HH Jr. 1993. Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1. N Engl J Med 328:1163-1165.
6. Fitzgibbon JE, Howell RM, Haberzettl CA, Sperber SJ, Gocke DJ, Dubin DT. 1992. Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2′, 3′-dideoxycytidine. Antimicrob Agents Chemother 36:153-157.
7. Frenkel LM, Wagner LE, Atwood SM, Cummins TJ, Dewhurst S. 1995. Specific, sensitive, and rapid assay for human immunodeficiency virus type 1 pol mutations associated with resistance to zidovudine and didanosine. J Clin Microbiol 33:342-347.
8. Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT, Haubrich RH, Henry WK, Lederman MM, Phair JP, Niu M, Hirsch MS, Merigan TC. 1996. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200-500 per cubic millimeter. N Engl J Med 335:1081-1090.
9. Hooker DJ, Tachedjian G, Solomon AE, Gurusinghe AD, Land S, Birch C, Anderson JL, Roy BM, Arnold E, Deacon NJ. 1996. An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3′-azido-3′-deoxythymidine. J Virol 70: 8010-8018.
10. Japour AJ, Mayer DL, Johnson VA, Kuritzkes DR, Beckett LA, Arduino J-M, Lane J, Black RJ, Reichelderfer PS, D'Aquila RT, Crumpacker CS. 1993. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother 37:1095-1101.
11. Kaye S, Loveday C, Tedder RS. 1992. A microtiter format point mutation assay: application to the detection of drug resistance in human immunodeficiency virus type-1 infected patients treated with zidovudine. J Med Virol 37:241-246.
12. Larder BA, Kemp SD. 1989. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246:1155-1158.
13. Larder BA, Darby G, Richman DD. 1989. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243:1731-1734.
14. Larder BA, Kellam P, Kemp SD. 1991. Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. AIDS 5:137-144.
15. Leitner T, Halapi E, Scarlatti G, Rossi, Albert J, Fenyö E-M, Uhlen M. 1993 Analysis of heterogenous viral populations by direct DNA sequencing. Biotechniques 15:120-127.
16. Nijhuis M, Schuurman R, de Jong D, van Leeuwen R, Lange J, Danner S, Keulen W, de Groot T, Boucher CA. 1997. Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co.resistant to zidovudine in vivo. J Inf Dis 176:398-405.
17. + lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. Ann Int Med 126:939-945.
18. Rubio A, Leal M, Pineda JA, Caruz A, Luque F, Key C, Sanchez-Quijano A, Lissen E. 1997. Increase in the frequency of mutation at codon 215 associated with zidovudine resistance in HIV-1 infected antiviral-naive patients from 1989 to 1996. AIDS 11:1184-1186.
19. Saag MS, Holodniy M, Kuritzkes DR, O'Brien WA, Coombs R, Poscher ME, Jacobsen DM, Shaw GM, Richman DD, Volberding PA. 1996. HIV viral load markers in clinical practice. Nat Med 2:625-629.
20. Schinazi RF, Larder BA, Mellors JW. 1996. Mutations in retroviral genes associated with drug resistance. Int Antivir News 4:95-107.
21. Schuurman R. 1997. State of the art of genotypic HIV-1 drug resistance. Curr Opin Inf Dis 10:480-484.
22. Shafer, RW, Kozal MJ, Winters MA, Iversen AK, Katzenstein DA, Ragni MV, Meyer WA III, Gupta P, Rasheed S, Coombs R, Katzman M, Fiscus S, Merigan TC. 1994. Combination therapy with zidovudine and didanosine selects for drug resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. J Inf Dis 169:722-729.
23. St. Clair MH, Martin JL, Tudor-Williams G, Bach MC, Vavro CL, King DM, Kellam P, Kemp SD, Larder BA. 1991. Resistance to ddl and sensitivity to AZT induced by a mutation in HIV reverse transcriptase. Science 253:1557-1559.
24. Stuyver L, Wyseur A. Rombout A, Louwagie J, Scarcez T, Verhofstede C, Rimland D, Schinazi RF, Roussau R. 1997. Line probe assay for rapid detection of drug selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene. Antimicrob Agents Chemother 41:284-291.
25. Tisdale M, Kemp SD, Parray NR, Larder BA. 1993. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci 90:5653-5656.